Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05004727 · ClinicalTrials.gov registry record · Phase 4
Multi-Center PAMPA Study
A Phase 4 study of Psoriasis, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 176
- Enrollment target
- 5
- Study locations
NCT05004727: Recruiting Phase 4 study of Psoriasis, sponsored by NYU Langone Health.
NCT05004727 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 176 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (64% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05004727, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 176 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
Primary Outcome
Score is defined by the ultrasound (General Electric Logiq E9 or E10) equipment, not calculated through a scale.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab
Study Locations (5)
New York
- NYU Langone Health - New York
- University of Rochester Medical Center (URMC) - Rochester
Massachusetts
- Brigham and Women's Hospital - Boston
Newfoundland and Labrador
- Memorial University - St. John's
Ontario
- Women's College Research Institute, University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 4 |
What NCT05004727 shows while recruiting
NCT05004727 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05004727 lists 5 locations in 4 states (New York, Massachusetts, Newfoundland and Labrador).
Frequently Asked Questions
What is clinical trial NCT05004727 about?
NCT05004727 is a clinical study titled "Multi-Center PAMPA Study". This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that ...
What is the current status of trial NCT05004727?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 176 participants. The study started on 2022-02-16. Estimated completion is 2028-07-31.
What conditions does trial NCT05004727 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05004727?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05004727?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05004727 being conducted?
This trial has 5 study locations across Massachusetts, New York, Newfoundland and Labrador, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05004727's enrollment target sits among peer trials
176 43rd of 125 higher than 83 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI